ung function and respiratory muscle strength in patients with heart failure with reduced, midrange and preserved leftventricular ejection fractio

• Conditions: I50; Heart failure

• Registration Number: DRKS00013898
• Lead Sponsor: Department für Neurologie - Klinik für Schlafmedizin und neuromuskuläre Erkrankungen (Direktor: Univ.-Prof. Dr. med. Peter Young)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-03-21
• Study Completion: 2019-06-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

a. Age > 18 years (no age limit) (Group 1, 2 and 3)
b. able to consent (Group 1, 2 and 3)
c. Diagnosis of HFrEF, HFmrEF and HFpEF according to the most recent Guidelines of the European Society of Cardiology (ESC); >12 weeks since the diagnosis of HF has been made; no hospitalisation for HF in the last 4 weeks; optimal medical therapy in accordance with the most recent Guidelines of the European Society of Cardiology (ESC) with no change in medication in the last 4 weeks and combination therapy fo HFrEF -where there was no treatment with beta blockers or ACE Inhibitors/ARBs in HFrEF, then the reason must be documented)
d. Controls (matched for age and gender) with normal findings on echocardiogram, electrocardiogram and normal levels of natriuretic peptide hormone (Group 4)

Exclusion Criteria

- Body Mass Index (BMI) > 35
- Chronic obstructive pulmonary disease, emphysema
- Presence of severe neurological comorbidities especially primary myopathy, muscular dystrophy, motor neuron disease, phrenic nerve disease, epilepsy, multiple sclerosis, parkinson’s disease
- Severe psychiatric disease including dementia
- Thoracic wall disease
- Cardiac pacemaker

Study & Design

• Study Type: observational
• Study Design: Not specified